ERM-DA483/IFCC: A new certified reference material for autoimmune antibodies
JRC releases a new serum protein certified reference material which has been developed in collaboration with the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) for the standardisation of measurements of immunoglobulin G proteinase 3 anti-neutrophil cytoplasmic autoantibodies (IgG PR3 ANCA). These antibodies represent the cornerstones of the diagnosis and monitoring of small vessel-associated vasculitis together with IgG MPO ANCA.
Small-vessel associated vasculitis includes three distinct forms; granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). Despite their common characteristics, they cannot be diagnosed with the same biomarker.
IgG PR3 ANCA are found in about 80% of patients with GPA. The newly developed CRM (ERM®-DA483/IFCC) serves as a biomarker mostly for this disease subform and it was developed so as to complete the gap that was left after the release of our previous CRM against IgG MPO ANCA (a biomarker mostly for the detection of MPA and EGPA).
Despite the importance of autoimmune antibodies in laboratory medicine and their routine analysis, the diversity in the measurement results from different methods remains vast. The immunoassays used for such measurements can be sensitive and specific, and are convenient in a clinical setting. However, the measurement signal is depending on a large number of factors such as antibody specificity, reaction kinetics and equilibria, multimeric state of the proteins, matrix effects, etc. Therefore the quantification with immunoassays requires the use of a well-designed and carefully characterised calibrant.
The EU Directive on In Vitro Diagnostic Medical Devices (IVD-MD) (Directive 98/79/EC) requires traceability of calibrants and control materials to reference measurement procedures and/or reference materials of higher order. There are already materials designated for calibration, but they are not fully characterised and often inconsistently used. This generates large variability in the measurement results and a potential delay in the diagnosis and subsequent follow-up of the disease.
The new reference material ERM®-DA483/IFCC was processed, characterised and certified in accordance to ISO Guide 34:2009. An inter-laboratory comparison exercise was performed with adherence to the quality requirements of ISO/IEC 17025. Details about material sampling, processing, characterisation and certification are described in the certification report, available together with the certificate in our online catalogue.
Related news
-
Creative Proteomics Lipidomics Announces Exosomes Lipidomics Service to Identify Lipid-based Biomarkers
Lipidomics, a division of Creative Proteomics, is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnology and pharmaceutical companies. The product manager has recently announced the fully-developed exosomes lipidomics service to help identify lipid-based biomarkers and unravel its monitoring function in diseases. Exosomes are considered to be a new and effective intercellular communication carrier. Adjacent cells or distant cells...
-
Creative Proteomics Announces the Launch of Its New Metabolomics Division
Creative Proteomics is an integrated company that provides proteomics, metabolomics, glycomics, and bioinformatics analysis services to researchers in the pharmaceutical, biotechnology, agriculture and nutrition industries, as well as academic and government organizations. With the aim of developing efficient metabolomics services to better support customer’s research, after hard work and dedication, Creative Proteomics is very excited to announce the launch of the newly-developed metabolomics division...
-
Creative Proteomics Offers Untargeted Metabolomics Service for Academia and Various Industries
Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS based metabolomics services for biomedical research institutions, biotechnology and pharmaceutical companies. Creative Proteomics has deep industry and business process expertise, global resources, and a good reputation in providing contract services specialized for metabolomics. Recently, the company announced the untargeted metabolomics service, which is a powerful tool for large-scale early phase diagnosis and...
-
Second Genome Presents Preclinical Data Demonstrating the Effects of Microbial-Derived Metabolites in Autism Spectrum Disorder
Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers based on novel microbial genetic insights, presented data from the largest analysis of microbiome function in Autism Spectrum Disorder (ASD), as well as preclinical activity of microbially-derived metabolites predicted to be reduced in ASD, during an oral poster presentation entitled, Predicted Metabolites from Multiple Microbiome Sequencing Datasets Modulate Autism...
-
Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers
Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, today announced they are entering a strategic collaboration with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) to identify microbiome biomarkers associated with clinical response for their lead program in gastroenterology, etrasimod. Under the terms of the agreement, Second Genome will utilize its proprietary sg-4sight...
Customer comments
No comments were found for ERM-DA483/IFCC: A new certified reference material for autoimmune antibodies. Be the first to comment!